This is a summary of the European public assessment report (EPAR) for Mavenclad. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Mavenclad. For practical information about using Mavenclad, patients should read the package leaflet or contact their doctor or pharmacist.
Therapeutic Indication
### Therapeutic indication Treatment of adult patients with highly active relapsing multiple sclerosis (MS) as defined by clinical or imaging features.
Therapeutic Area (MeSH)
ATC Code
L04AA40
ATC Item
cladribine
Pharmacotherapeutic Group
Immunosuppressants
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| Cladribine | N/A | 克拉屈滨 |
EMA Name
Mavenclad
Medicine Name
Mavenclad
Aliases
N/A
